Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02823990 · ClinicalTrials.gov registry record · Phase 2
TG4010 and Nivolumab in Patients With Lung Cancer
A Phase 2 study, sponsored by Megan Daly, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02823990 is a Phase 2 study that has completed, run by Megan Daly, MD. The registered enrollment target is 13 participants.
The verdict
NCT02823990, a Phase 2 study, has completed, sponsored by Megan Daly, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as nivolumab, interfere with the ability of tumor cells to grow and spread. Giving TG4010 and nivolumab together may work better in previously treated patients with non-small cell lung cancer.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL TG4010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2021-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02823990
The ClinicalTrials.gov registry entry for NCT02823990 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Megan Daly, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02823990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02823990 about?
NCT02823990 is a clinical study titled "TG4010 and Nivolumab in Patients With Lung Cancer". This phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as n...
What is the current status of trial NCT02823990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2016-12-14. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT02823990?
The interventions under investigation include: Nivolumab (BIOLOGICAL), TG4010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02823990?
This trial is sponsored by Megan Daly, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.